Silencing of PAX2 led to an increase in SRC-3/AIB1 bound to the HER-2 enhancer and significantly higher levels of HER-2 mRNA levels during tamoxifen treatment in breast cancer cell lines [30]. This evidence concerns the gene PAX2 and breast cancer.